<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:57:51Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4527731" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4527731</identifier><datestamp>2015-08-12</datestamp><setSpec>plosone</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, CA USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4527731</article-id>
      <article-id pub-id-type="pmcid">PMC4527731</article-id>
      <article-id pub-id-type="pmc-uid">4527731</article-id>
      <article-id pub-id-type="pmid">26248042</article-id>
      <article-id pub-id-type="pmid">26248042</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0134569</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-15-24665</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Calcineurin Undergoes a Conformational Switch Evoked via Peptidyl-Prolyl Isomerization</article-title>
        <alt-title alt-title-type="running-head">Calcineurin Conformational Change</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Guasch</surname>
            <given-names>Alicia</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aranguren-IbÃ¡Ã±ez</surname>
            <given-names>Ãlvaro</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>PÃ©rez-Luque</surname>
            <given-names>Rosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aparicio</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MartÃ­nez-HÃ¸yer</surname>
            <given-names>Sergio</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
          <xref ref-type="author-notes" rid="currentaff001">
<sup>Â¤a</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mulero</surname>
            <given-names>M. Carmen</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
          <xref ref-type="author-notes" rid="currentaff002">
<sup>Â¤b</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Serrano-Candelas</surname>
            <given-names>Eva</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
          <xref ref-type="author-notes" rid="currentaff003">
<sup>Â¤c</sup>
</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>PÃ©rez-Riba</surname>
            <given-names>MercÃ¨</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
          <xref rid="cor001" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Fita</surname>
            <given-names>Ignacio</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
          <xref rid="cor001" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="aff001">
<label>1</label>
<addr-line>Institut de Biologia Molecular de Barcelona (IBMB-CSIC), Parc CientÃ­fic, Baldiri Reixac 10, 08028, Barcelona, Spain</addr-line>
</aff>
      <aff id="aff002">
<label>2</label>
<addr-line>Human Molecular Genetics Laboratory, Institut dâInvestigaciÃ³ BiomÃ¨dica de Bellvitge (IDIBELL), Gran Via de LâHospitalet 199, LâHospitalet de Llobregat, 08908, Barcelona, Spain</addr-line>
</aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Wlodawer</surname>
            <given-names>Alexander</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
<addr-line>NCI-Frederick, UNITED STATES</addr-line>
</aff>
      <author-notes>
        <fn fn-type="COI-statement" id="coi001">
          <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="con" id="contrib001">
          <p>Conceived and designed the experiments: IF MPR. Performed the experiments: AG AAI MCM RPL ESC DA SMH. Analyzed the data: AG IF. Wrote the paper: IF MPR. Reviewed the manuscript: AG ÃAI RPL DA SMH MCM ESC MPR IF.</p>
        </fn>
        <fn fn-type="current-aff" id="currentaff001">
          <label>Â¤a</label>
          <p>Current address: BC Cancer Research Centre, 675 W 10th Ave, Vancouver, V5Z 1L3, Canada</p>
        </fn>
        <fn fn-type="current-aff" id="currentaff002">
          <label>Â¤b</label>
          <p>Current address: Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States of America</p>
        </fn>
        <fn fn-type="current-aff" id="currentaff003">
          <label>Â¤c</label>
          <p>Current address: Biochemistry Unit, Faculty of Medicine, University of Barcelona, Casanova 143, 08036, Barcelona, Spain</p>
        </fn>
        <corresp id="cor001">* E-mail: <email>ifrcri@ibmb.csic.es</email> (IF); <email>mpr@idibell.cat</email> (MPR)</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>6</day>
        <month>8</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>10</volume>
      <issue>8</issue>
      <elocation-id>e0134569</elocation-id>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>6</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>7</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2015 Guasch et al</copyright-statement>
        <copyright-year>2015</copyright-year>
        <copyright-holder>Guasch et al</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0134569.pdf"/>
      <abstract>
        <p>A limited repertoire of PPP family of serine/threonine phosphatases with a highly conserved catalytic domain acts on thousands of protein targets to orchestrate myriad central biological roles. A major structural reorganization of human calcineurin, a ubiquitous Ser/Thr PPP regulated by calcium and calmodulin and targeted by immunosuppressant drugs cyclosporin A and FK506, is unveiled here. The new conformation involves <italic>trans-</italic> to <italic>cis-</italic> isomerization of proline in the SAPNY sequence, highly conserved across PPPs, and remodels the main regulatory site where NFATc transcription factors bind. Transitions between <italic>cis-</italic> and <italic>trans-</italic> conformations may involve peptidyl prolyl isomerases such as cyclophilin A and FKBP12, which are known to physically interact with and modulate calcineurin even in the absence of immunosuppressant drugs. Alternative conformations in PPPs provide a new perspective on interactions with substrates and other protein partners and may foster development of more specific inhibitors as drug candidates.</p>
      </abstract>
      <funding-group>
        <funding-statement>This work was supported by grants SAF2009-08216-BFU2012-36827 from Ministerio de Ciencia e InnovaciÃ³n and 2009SGR1490-2014SGR987 from the Generalitat de Catalunya. A. A.-I. was a recipient of an FI PhD fellowship from Generalitat de Catalunya.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="7"/>
        <table-count count="2"/>
        <page-count count="15"/>
      </counts>
      <custom-meta-group>
        <custom-meta id="data-availability">
          <meta-name>Data Availability</meta-name>
          <meta-value>Structural data reported in this article is archived at the RCSB Protein Database, under reference 5C1V.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <title>Data Availability</title>
      <p>Structural data reported in this article is archived at the RCSB Protein Database, under reference 5C1V.</p>
    </notes>
  </front>
  <body>
    <sec sec-type="intro" id="sec001">
      <title>Introduction</title>
      <p>Reversible phosphorylation, orchestrated by the opposing activities of kinases and phosphatases, is estimated to occur in about one-third of proteins and is responsible for modulating many cellular functions including cell growth, proliferation and differentiation [<xref rid="pone.0134569.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0134569.ref002" ref-type="bibr">2</xref>]. Phosphoserine and phosphothreonine, which account for over 98% of protein-bound phosphate in eukaryotic cells, are regulated by a large number of Ser/Thr protein kinases and, surprisingly, far fewer Ser/Thr phosphatases including, in particular, the widely distributed family of phosphoprotein phosphatases (PPPs), encoded by a relatively small number of genes in the human genome[<xref rid="pone.0134569.ref003" ref-type="bibr">3</xref>]. Protein phosphatase 1 (PP1), with more than two hundred confirmed targeting proteins, and calcineurin (PPP3C, formerly PP2B) are the most abundant and extensively studied PPPs [<xref rid="pone.0134569.ref004" ref-type="bibr">4</xref>].</p>
      <p>Calcineurin (CN), ubiquitously expressed and highly conserved from yeast to humans, plays a critical role coupling Ca<sup>2+</sup> signals to different gene expression patterns and cellular responses[<xref rid="pone.0134569.ref005" ref-type="bibr">5</xref>]. CN was first identified as the target of the immunosuppressants cyclosporine A (CsA) and FK506[<xref rid="pone.0134569.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0134569.ref007" ref-type="bibr">7</xref>], which are the cornerstone of current immunosuppressive therapy. These drugs bind to the endogenous immunophilins cyclophilin A (CypA) and FKBP12[<xref rid="pone.0134569.ref008" ref-type="bibr">8</xref>], respectively, and the corresponding complexes bind to CN inhibiting phosphatase activity for all CN substrates resulting in both desired therapeutic outcomes and in some cases severe side-effects[<xref rid="pone.0134569.ref009" ref-type="bibr">9</xref>]. CN functions as an heterodimer with a large catalytic subunit (CNA) (59 kDa for the human Î± isoform) interacting with two Ca<sup>2+</sup> binding proteins, calmodulin and the small regulatory CN subunit (CNB) (19 kDa for the type 1 isoform)[<xref rid="pone.0134569.ref005" ref-type="bibr">5</xref>]. CNA is organized as an N-terminal catalytic domain, of about three hundred residues, and a C-terminal regulatory domain comprising the CNB and the calmodulin binding regions followed by an autoinhibitory domain (AID) that, under specific conditions, binds into the active site blocking the access of substrates [<xref rid="pone.0134569.ref010" ref-type="bibr">10</xref>]. The catalytic domain of CNA presents a high sequence and structural homology to other PPP catalytic domains [<xref rid="pone.0134569.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0134569.ref012" ref-type="bibr">12</xref>]. The active site contains two metal ions located between two helical domains and a characteristic central sandwich of two Î²-sheets that are interconnected between strands Î²12 (from sheet I) and Î²13 (from sheet II) by a highly conserved sequence (FSAPNYxxxxxNx) (<xref rid="pone.0134569.g001" ref-type="fig">Fig 1a</xref>)[<xref rid="pone.0134569.ref013" ref-type="bibr">13</xref>]. The Î²12-Î²13 connection, also called loop 7 in CNA, is one of the key regulatory elements in PPPs [<xref rid="pone.0134569.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0134569.ref015" ref-type="bibr">15</xref>].</p>
      <fig id="pone.0134569.g001" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0134569.g001</object-id>
        <label>Fig 1</label>
        <caption>
          <title>Sequence and structural alignments.</title>
          <p>(<bold>a</bold>) The catalytic domain of CNA is highly conserved around the Î²12 and Î²13 connection in PPPs. Sequence alignments around the Î²12 and Î²13 connection of the catalytic domains of human PPPs. PPP1 to PPP7, protein phosphatases 1 to 7; PPEF1 and 2, protein phosphatase EF-hand calcium binding domain 1 and 2; and CPPED1, calcineurin-like phosphoesterase domain containing 1. A, B and C correspond to Î±, Î² and Î³ isozymes, respectively. Alignment were performed using MAFFT v.7 online version (<ext-link ext-link-type="uri" xlink:href="http://mafft.cbrc.jp/alignment/software/">http://mafft.cbrc.jp/alignment/software/</ext-link>)[<xref rid="pone.0134569.ref038" ref-type="bibr">38</xref>] using default parameters and subsequently edited using Jalview software v.2.8[<xref rid="pone.0134569.ref039" ref-type="bibr">39</xref>]. (<bold>b</bold>) Structural alignment of <italic>cis</italic>-CNA (brown) and <italic>trans</italic>-CNA (blue) showing the sequence shifts and the secondary structural elements correspondence. Small letters indicate amino acid residues not modeled in the structure. Residues from loops 6 and 7 are shadowed in the <italic>trans</italic>-CNA conformation.</p>
        </caption>
        <graphic xlink:href="pone.0134569.g001"/>
      </fig>
      <p>The cytosolic Nuclear Factor of Activated T cells (NFATc) transcription factors, critical in many cellular processes, bind to CN through two binding sequences, the PxIxIT and LxVP motifs[<xref rid="pone.0134569.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0134569.ref017" ref-type="bibr">17</xref>], and at least one of them is present in all the endogenous CN modulators identified so far[<xref rid="pone.0134569.ref018" ref-type="bibr">18</xref>]. The structures of a diversity of CN constructs alone or in complex with FK506/FKBP12[<xref rid="pone.0134569.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0134569.ref012" ref-type="bibr">12</xref>], CsA/CypA[<xref rid="pone.0134569.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0134569.ref020" ref-type="bibr">20</xref>], or with different peptides, have been determined[<xref rid="pone.0134569.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0134569.ref021" ref-type="bibr">21</xref>â<xref rid="pone.0134569.ref023" ref-type="bibr">23</xref>]. Regulatory PxIxIT-containing peptides add a strand at the Î²14 edge of Î²-sheet II. Similarly, PP1 phosphatase recognizes an RVxF motif in its targeting subunits through binding at a site cognate to the PxIxIT-binding site [<xref rid="pone.0134569.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0134569.ref024" ref-type="bibr">24</xref>].</p>
    </sec>
    <sec sec-type="materials|methods" id="sec002">
      <title>Materials and Methods</title>
      <sec id="sec003">
        <title>Materials</title>
        <p>Peptides were purchased from the Peptide 2.0 Company (Chantilly, VA) and synthesized as acetylated N-terminal and C-terminal amides for the unlabeled peptides and N-carboxyfluorescein (CF) and C-terminal amide for the labelled peptide. The sequences of the peptides used are the following: <monospace>KYELHAGTESTPSVVVHVCES</monospace> for the RCAN<sup>183â203</sup> peptide; <monospace>NNKAAVLKYE</monospace> for the <italic>cis</italic>-CNA derived peptide; and <monospace>ASGLSPRIEITPSHEL</monospace> for the <monospace>NFATc2-SPRIEIT (SPRIEIT)</monospace> peptide. All peptides were resuspended in 100% DMSO at 10 mM. Cyclosporin A (CsA) was obtained from Sandoz. Ionomycin (Io) sodium salt and Phorbol 12-myristate 13-acetate sodium salt (PMA) were obtained from Sigma. The anti-calcineurin A antibody was purchased from BD Biosciences and the anti-Flag M2 antibody was purchased from Sigma. The protease and phosphatase inhibitor cocktails were from Calbiochem.</p>
      </sec>
      <sec id="sec004" sec-type="materials|methods">
        <title>Methods</title>
        <sec id="sec005">
          <title>Protein expression and purification</title>
          <p>Large scale production of the catalytic domain of CNA was achieved with the pGEX-6P-1-CNAÎ± plasmid construct, kindly provided by Patrick Hogan, that encodes the Glutathione S-transferase protein linked to the human CNA Î± isoform (NCBI NP_000935.1) catalytic domain (residues 2â347). Expression, purification and isolation of the CNAÎ± domain was performed as previously described[<xref rid="pone.0134569.ref025" ref-type="bibr">25</xref>]. The isolated CNAÎ± catalytic domain was further purified using a Superdex 75 size-exclusion column equilibrated at 0.4 ml/min with 100 mM NaCl and 50 mM Tris pH 8.0, where the protein eluted as a unique peak corresponding to 40 kDa. The purified protein was kept at 4Â°C for short periods of time.</p>
        </sec>
        <sec id="sec006">
          <title>Protein crystallization and structure determination</title>
          <p>Hexagonal crystals were obtained by vapour diffusion, using the human CNAÎ± catalytic domain a final protein concentration of 7.3 mg/ml. Crystals (with a reservoir buffer of 0.1M HepesâpH 7.5 -, 26% PEG 3350 and 4% PGA) are in space group P6<sub>2</sub>22 with cell parameters of <bold>a</bold> = <bold>b</bold> = 185.01 Ã, <bold>c</bold> = 106.74 Ã and <bold>Î±</bold> = <bold>Î²</bold> = 90Â°, <bold>Î³</bold> = 120Â°. Crystals were cryoprotected using reservoir solution supplemented with 20% (v/v) glycerol and flash-cooled in liquid nitrogen. X-ray diffraction data, collected at 100K on beam line PROXIMA-1 (SOLEIL synchrotron, France) with a Dectris Pilatus 6M detector and oscillation angles of 0.2Â° per frame, were processed using the interactive iMOSFLM package at 3.35 Ã resolution[<xref rid="pone.0134569.ref026" ref-type="bibr">26</xref>]. Crystals, with similar unit cell parameters, have also been obtained in the absence of inhibitory peptides, though diffraction from these crystals was always below 3.5 Ã resolution.</p>
          <p>The structure was solved by molecular replacement using <italic>MOLREP</italic>[<xref rid="pone.0134569.ref027" ref-type="bibr">27</xref>] and the coordinates of human CN (PDB entry 1AUI) as search model. Refinement was performed with <italic>REFMAC5</italic>[<xref rid="pone.0134569.ref028" ref-type="bibr">28</xref>] and the molecular-graphics program <italic>COOT</italic>[<xref rid="pone.0134569.ref029" ref-type="bibr">29</xref>] (<xref rid="pone.0134569.t001" ref-type="table">Table 1</xref>). Non-crystallographic restraints together with the restraints of the <italic>trans</italic>-CNA subunit towards high resolution information were also applied.</p>
          <table-wrap id="pone.0134569.t001" orientation="portrait" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0134569.t001</object-id>
            <label>Table 1</label>
            <caption>
              <title>X-ray Data and Refinement statistics.</title>
            </caption>
            <alternatives>
              <graphic id="pone.0134569.t001g" xlink:href="pone.0134569.t001"/>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <tbody>
                  <tr>
                    <td colspan="2" align="left" rowspan="1">
<bold>A</bold>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">
<bold>X-ray Data</bold>
</td>
                    <td align="left" rowspan="1" colspan="1">CNA</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Resolution limits (Ã)</td>
                    <td align="left" rowspan="1" colspan="1">50.0â3.35 (3.53â3.35)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Space group</td>
                    <td align="left" rowspan="1" colspan="1">P6<sub>2</sub> 2 2</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Unit cell parameters (Ã, Â°)</td>
                    <td align="left" rowspan="1" colspan="1">185.01, 185.01, 106.74 90, 90, 120</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">R pim (%)</td>
                    <td align="left" rowspan="1" colspan="1">5.2 (33.6)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Completeness (%)</td>
                    <td align="left" rowspan="1" colspan="1">100 (100)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">&lt;I/Ï(I)&gt;</td>
                    <td align="left" rowspan="1" colspan="1">13.0 (2.7)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Multiplicity</td>
                    <td align="left" rowspan="1" colspan="1">17.1 (15.7)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">NÂ° of unique reflections</td>
                    <td align="left" rowspan="1" colspan="1">15.994 (2.270)</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Total number of observations</td>
                    <td align="left" rowspan="1" colspan="1">272.976 (33.646)</td>
                  </tr>
                  <tr>
                    <td colspan="2" align="justify" rowspan="1">
<bold>B</bold>
</td>
                  </tr>
                  <tr>
                    <td align="justify" rowspan="1" colspan="1">
<bold>Refinement</bold>
</td>
                    <td align="justify" rowspan="1" colspan="1">CNA</td>
                  </tr>
                  <tr>
                    <td align="justify" rowspan="1" colspan="1">Resolution limits (Ã)</td>
                    <td align="justify" rowspan="1" colspan="1">50.0â3.35</td>
                  </tr>
                  <tr>
                    <td align="justify" rowspan="1" colspan="1">Rwork (%)</td>
                    <td align="justify" rowspan="1" colspan="1">21.56</td>
                  </tr>
                  <tr>
                    <td align="justify" rowspan="1" colspan="1">Rfree (%)</td>
                    <td align="justify" rowspan="1" colspan="1">24.91</td>
                  </tr>
                  <tr>
                    <td align="justify" rowspan="1" colspan="1">Rms bond lengths (Ã)</td>
                    <td align="justify" rowspan="1" colspan="1">0.017</td>
                  </tr>
                  <tr>
                    <td align="justify" rowspan="1" colspan="1">Rms bond angles (Â°)</td>
                    <td align="justify" rowspan="1" colspan="1">2.1</td>
                  </tr>
                  <tr>
                    <td align="justify" rowspan="1" colspan="1">NÂ° of protein atoms</td>
                    <td align="justify" rowspan="1" colspan="1">5.064</td>
                  </tr>
                  <tr>
                    <td align="justify" rowspan="1" colspan="1">Protein mean B-factor (Ã<sup>2</sup>)</td>
                    <td align="justify" rowspan="1" colspan="1">48</td>
                  </tr>
                </tbody>
              </table>
            </alternatives>
            <table-wrap-foot>
              <fn id="t001fn001">
                <p>* In brackets for the last resolution shell.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="sec007">
          <title>Fluorescence polarization</title>
          <p>Competition assays were performed as described[<xref rid="pone.0134569.ref030" ref-type="bibr">30</xref>]. Briefly, carboxyfluorescein (CF)-SPRIEIT-CNA complex was performed using 10 nM of CF-labeled SPRIEIT peptide and 10 Î¼M CNA. Unlabeled competitor peptides were pre-incubated with CNA at increasing concentrations for 15 min before adding the fluorescence labeled peptide. Experiments were performed in a OptiPlate black 384-well-flat-bottom plates (PerkinElmer Life Sciences, Waltham, MA) and measured using a Wallac VICTOR (TM) X5 2030 Multilabel Reader (PerkinElmer Life Sciences) with excitation and emission wavelengths of 485 nm and 535 nm respectively. All assays were performed for 15 min at room temperature. All data were obtained from at least three independent experiments performed in triplicates.</p>
        </sec>
        <sec id="sec008">
          <title>GST-pull-down competition assays</title>
          <p>In GST-RCAN3 pull-down competition assays, HEK 293T cells were lysed in co-immunoprecipitation buffer (50 mM TrisâHCl, pH 7.5, 100 mM NaCl, 2 mM CaCl<sub>2</sub>, 5 mM MgCl<sub>2</sub>, 1% IGEPAL, 1 mM DTT, 2 mM PMSF and protease and phosphatase inhibitor cocktails) and the CNA- and the RCAN3-derived peptides containing a PxIxIT sequence were added to the extracts at the indicated concentrations for 30 min. Then, the soluble extracts were incubated with GSTâRCAN3 bound to Glutathione Sepharose beads for 90 min at 4Â°C. After extensive washing, co-precipitated proteins were eluted by resuspension in 2Ã Laemmli buffer and boiled for 10 min. For GSTâNFATc2 pull-down competition assays, HEK 293T cells transfected with FLAGâCNA (2â389) were lysed in a buffer containing 50 mM TrisâHCl, pH 8, 100 mM NaCl, 1.5 mM CaCl<sub>2</sub>, 6 mM MgCl<sub>2</sub>, 0.2% TX-100, 1 mM PMSF and protease and phosphatase inhibitor cocktails. Soluble extracts were incubated with GSTâNFATc2 bound to Glutathione Sepharose beads for 60 min at 4Â°C.</p>
        </sec>
        <sec id="sec009">
          <title>NFATc-luciferase reporter gene assay</title>
          <p>Flag-hCNAÎ± mutants were performed by PCR using CN specific primers (<xref rid="pone.0134569.t002" ref-type="table">Table 2</xref>). ÎNIR mutant lacks the CNA PXIXIT binding region VMNIR ranging from amino acids 328 to 332. All Flag-CNA constructs bear the Y341F mutation to achieve CsA resistance unless for the specified wt. Luciferase gene assays were performed in HEK 293T cells transfected with 100 ng of 3xNFAT-luc plasmid, 100 ng of pBJ5-mCNB, 1 ng of pRLNull as an internal transfection control and 400 ng of the indicated Flag-hCNAÎ± mutants constructs. Stimulation was achieved by treating the cells with.1 Î¼M ionomycin, 10 nM PMA and 10 mM CaCl<sub>2</sub>. Endogenous CN activity was abolished by treating cells with 1 Î¼M Cyclosporin A (CsA) 30 min prior to stimulation. FK506 was used as a positive control for CsA-resistant CN. After 6h of cell stimulation, 10 Î¼l of cell extract were analyzed for luciferase gene expression using the Dual-Luciferase Reporter Assay (Promega) following the manufacturerâs protocol on a multiplate luminometer (FLUOstar Optima, BMG). Luciferase units were normalized to densitometric data of 10 Î¼l of cell extract analyzed by western blot. Absence of cell stimulation is shown with a minus symbol (-). Three experiments were performed with triplicates. Stimulation of the Y341F mutant was considered as 100% value.</p>
          <table-wrap id="pone.0134569.t002" orientation="portrait" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pone.0134569.t002</object-id>
            <label>Table 2</label>
            <caption>
              <title>Oligonucleotide designation and sequence.</title>
            </caption>
            <alternatives>
              <graphic id="pone.0134569.t002g" xlink:href="pone.0134569.t002"/>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" rowspan="1" colspan="1">Primer name</th>
                    <th align="left" rowspan="1" colspan="1">Sequence</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-Y341F-Fw</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>GCAATTCAACTGTTCTCCTCATCCATTCTGGCTTCCAAATT</monospace>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-Y341F-Rv</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>AATTTGGAAGCCAGAATGGATGAGGAGAACAGTTGAATTGC</monospace>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-Y288N-Fw</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>CCCAGATGCAGGGAACCGCATGTACAGG</monospace>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-Y288N-Rv</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>CCTGTACATGCGGTTCCCTGCATCTTGGG</monospace>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-Y288F-Fw</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>GAAGCCCAAGATGCAGGGTTCCGCATGTAC</monospace>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-Y288F-Rv</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>GTACATGCGGAACCCTGCATCTTGGGCTTC</monospace>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-Y288A-Fw</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>GAAGCCCAAGATGCAGGGGCCCGCATGTACAGGAAAAG</monospace>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-Y288A-Rv</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>CTTTTCCTGTACATGCGGGCCCCTGCATCTTGGGCTTC</monospace>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-ÎNIR-Fw</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>CAGTATTGAAGTATGAGAACAATCAATTCAACTGTTCTCCTCATCC</monospace>
</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">hCnA-ÎNIR-Rv</td>
                    <td align="left" rowspan="1" colspan="1">
<monospace>GGATGAGGAGAACAGTTGAATTGATTGTTCTCATACTTCAATACTG</monospace>
</td>
                  </tr>
                </tbody>
              </table>
            </alternatives>
          </table-wrap>
        </sec>
      </sec>
    </sec>
    <sec id="sec010">
      <title>Results and Discussion</title>
      <p>The structure of the catalytic domain of human CNAÎ± (residues 2â347) has been determined from hexagonal crystals. The two subunits of the catalytic domain contained in the asymmetric unit presenting important structural differences (<xref rid="pone.0134569.t001" ref-type="table">Table 1</xref>, <xref rid="pone.0134569.g002" ref-type="fig">Fig 2</xref>). The first subunit in the crystal shows the essentially invariant conformation (herein referred to as <italic>trans-</italic>CNA) found in all available structures of CN and other PPP phosphatases. The second subunit in the crystal shows an alternative new conformation (herein referred to as <italic>cis-</italic>CNA) (<xref rid="pone.0134569.g002" ref-type="fig">Fig 2a</xref>). The two subunits in the asymmetric unit are related by a non-crystallographic quasi-two-fold rotation (172Â°) plus a 3.7Ã translation, about an axis roughly in the middle of the Î²14 strands that interact with each other extending sheet II across both subunits (<xref rid="pone.0134569.g002" ref-type="fig">Fig 2b</xref>). The thirteen residues long connection (Phe306-Lys318) joining strands Î²12 and Î²13 in <italic>trans</italic>-CNA is reduced to a standard VIa-1 Î²-turn [<xref rid="pone.0134569.ref031" ref-type="bibr">31</xref>] with only four residues SAP<sub>309</sub>N in <italic>cis-</italic>CNA (Figs <xref rid="pone.0134569.g001" ref-type="fig">1a, 1b</xref> and <xref rid="pone.0134569.g002" ref-type="fig">2b</xref>). Residue Pro309 within the SAPNY sequence is a peptidyl <italic>trans</italic> isomer in <italic>trans-</italic>CNA, while it is a <italic>cis</italic> isomer in <italic>cis-</italic>CNA (<xref rid="pone.0134569.g003" ref-type="fig">Fig 3</xref>). Strands Î²13 and Î²14, downstream in sequence to Pro309, are still present in <italic>cis-</italic>CNA and superimpose structurally well with the same strands of <italic>trans-</italic>CNA, but the amino acid residues within these strands differ between <italic>trans</italic>-CNA and <italic>cis</italic>-CNA (Figs <xref rid="pone.0134569.g001" ref-type="fig">1b</xref>, <xref rid="pone.0134569.g003" ref-type="fig">3a and 3b</xref>). Strand Î²13 presents a ten residue shift between the two conformations with Asn310 in <italic>cis</italic>-CNA being structurally equivalent to Ala320 in <italic>trans</italic>-CNA. For the Î²14 strand the structurally equivalent residues present a nine residue shift with Ala319 in <italic>cis</italic>-CNA being structurally equivalent to Val328 in <italic>trans</italic>-CNA. Therefore, the nine residue shift increases the number of residues after Î²14 in <italic>cis</italic>-CNA with respect to <italic>trans</italic>-CNA. This region loops around the active site in <italic>cis</italic>-CNA, with side chains poorly defined, interacting also with neighboring subunits in the crystal. This region would correspond to the linker connecting the catalytic domain and the CNB binding region in full-length CNA. In <italic>trans</italic>-CNA, loop 7 and strand Î²13 interact with loop 6, which corresponds to residues from Ala280 to Gly287 between strands Î²10 and Î²11 including the catalytically essential residue His281[<xref rid="pone.0134569.ref002" ref-type="bibr">2</xref>] (<xref rid="pone.0134569.g001" ref-type="fig">Fig 1b</xref>). The decrease in the number of residues for the Î²12-Î²13 connection together with the amino acid sequence changes in strand Î²13, can explain the destabilization of loop 6 and of strand Î²11 that in <italic>cis</italic>-CNA are disordered from Ala283 until Arg289.</p>
      <fig id="pone.0134569.g002" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0134569.g002</object-id>
        <label>Fig 2</label>
        <caption>
          <title>Structures of the interacting CNA catalytic domains with <italic>trans-</italic> and <italic>cis-</italic> conformations.</title>
          <p>(<bold>a</bold>) Ribbon representation of two neighboring CNA subunits in the crystal presenting the <italic>trans-</italic> (blue) and <italic>cis-</italic> (brown) conformations, respectively. The metal atoms and the phosphate group in the active site are shown as spheres. (<bold>b</bold>) Sheets I and II topology corresponding to the <italic>cis</italic>- and <italic>trans</italic>-conformations of the catalytic domain of CNA with the relative position of the two subunits in the crystal showing the interaction between Î²14 strands. The pseudo two-fold axis (dashed blue arrow) relating both subunits is indicated. Î²13 and Î²14 strands in <italic>cis</italic>-CNA are shown with a different color (green) to emphasize that they differ from the ones in <italic>trans</italic>-CNA. The thirteen residues long loop 7 joining strands Î²12 and Î²13 in <italic>trans</italic>-CNA is reduced to a tight Î²-turn with only four residues (SAP<sub>309</sub>N) in <italic>cis-</italic>CNA.</p>
        </caption>
        <graphic xlink:href="pone.0134569.g002"/>
      </fig>
      <fig id="pone.0134569.g003" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0134569.g003</object-id>
        <label>Fig 3</label>
        <caption>
          <title>Complete reorganization of the Pro309 environment between the <italic>trans-</italic> and <italic>cis-</italic> conformations of CNA.</title>
          <p>Stereo views showing the large structural differences observed in the Pro309 environments between the (<bold>a</bold>) <italic>trans</italic>-CNA and (<bold>b</bold>) <italic>cis</italic>-CNA conformations. The (2Fo-Fc) electron density map, contoured at 1Ï and depicted in dark grey, and the (Fo-Fc) maps, contoured at 3Ï (positive in green and negative in red), are also shown for both CNA conformations. Residues from Phe299 to Asn326 and from Phe299 to Tyr315 are shown for <italic>trans</italic>-CNA (blue) and <italic>cis</italic>-CNA (brown), respectively. The corresponding molecular models are represented as thick rods while the superimposed structures of the alternative conformations are depicted as thin rods. Both conformations are essentially identical till residue Phe306, where only side chains differ significantly. Beyond Phe306 also main chains separate completely. (<bold>c</bold>) Superimposition of the structures of the-Ser-Ala-<italic>cis</italic>Pro-Asn- fragment forming the turn (within the SAPNY sequence), as found in <italic>cis-</italic>CNA (brown) and in the enzyme family 5 xyloglucanase (yellow) where the <italic>cis</italic> conformation adopted by the proline is accurately defined at 1.4 Ã resolution (PDB code 2JEP). The 2Fo-Fc electron density corresponding to the boxes in panel <bold>b</bold> is also shown to emphasize the quality of the fitting of <italic>cis-</italic>CNA residues around Pro309 (from Phe306 to Tyr311).</p>
        </caption>
        <graphic xlink:href="pone.0134569.g003"/>
      </fig>
      <p>Differences between <italic>trans</italic>-CNA and <italic>cis</italic>-CNA have major implications both on the active site organization and on the crucial docking site for PxIxIT-containing proteins. Concerning the active site, PP1 phosphatases have been described as containing two metal ions at the intersection of three putative substrate binding grooves, referred to as hydrophobic, acidic and C-terminal grooves[<xref rid="pone.0134569.ref024" ref-type="bibr">24</xref>]. Following on this description for CN (<xref rid="pone.0134569.g004" ref-type="fig">Fig 4a</xref>), loops 6 and 7 are located between the acidic and the C-terminal grooves forming the internal walls of these grooves in <italic>trans-</italic>CNA (<xref rid="pone.0134569.g004" ref-type="fig">Fig 4b</xref>). Instead, in <italic>cis</italic>-CNA the acidic and C-terminal binding grooves merge into a continuous surface, due to the reduction of loop 7 and the flexibility of loop 6, rendering the catalytic metal ions accessible to substrates with wider binding surfaces than for <italic>trans-</italic>CNA (<xref rid="pone.0134569.g004" ref-type="fig">Fig 4c</xref>). Moreover, in <italic>cis</italic>-CNA disordered residues from loop 6 and the enlarged linker define a new environment around the active site (<xref rid="pone.0134569.g004" ref-type="fig">Fig 4d</xref>). Residues from loop 7 (in particular Tyr311 and Tyr315) in <italic>trans</italic>-CNA participate in AID binding and consequently the absence of this loop 7 in <italic>cis</italic>-CNA should weaken or prevent AID binding and the corresponding inhibitory effects. Given that in <italic>cis</italic>-CNA the active site is more accessible than in <italic>trans</italic>-CNA, no significant differences in phosphatase activity are expected for the standard small substrates pNPP and RII peptide (from the regulatory RII subunit of cAMP-dependent protein kinase[<xref rid="pone.0134569.ref032" ref-type="bibr">32</xref>]). Concerning the PxIxIT binding site, in <italic>trans</italic>-CNA strand Î²14 defines the central structural element of the site with binding affinities that are finely tuned from both consensus and non-consensus positions in the motif[<xref rid="pone.0134569.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0134569.ref021" ref-type="bibr">21</xref>]. Accordingly, affinity for the PxIxIT binding site is redefined by the sequence shift between Î²14 strands in <italic>trans</italic>-CNA and <italic>cis</italic>-CNA (Figs <xref rid="pone.0134569.g001" ref-type="fig">1b</xref> and <xref rid="pone.0134569.g002" ref-type="fig">2b</xref>). Mutating residue Tyr288, a residue next to loop 6 that is disordered in cis-CNA and in trans-CNA interacts with Lys323 from Î²-13 and with Ile331 from Î²-14, to alanine or to asparagine decreases sharply NFATc activity (<xref rid="pone.0134569.g005" ref-type="fig">Fig 5</xref>). In turn, mutant of Tyr288 to phenylalanine, which can retain the hydrophobic interactions with Ile331, also retains a significant NFATc activity. Therefore, altering loop 6 results in the destabilization of trans-CNA and consequently of the CN PxIxIT binding site.</p>
      <fig id="pone.0134569.g004" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0134569.g004</object-id>
        <label>Fig 4</label>
        <caption>
          <title>Reorganization of the active site between <italic>trans</italic>- and <italic>cis-</italic> CNA.</title>
          <p>(<bold>a</bold>) Surface representation of a CNA subunit (grey), truncated after the CNB binding region, in complex with a CNB subunit (pink), with the binding sites for proteins containing LxVP and for PxIxIT (green) motifs [<xref rid="pone.0134569.ref018" ref-type="bibr">18</xref>]. A bound autoinhibitory domain is also explicitly indicated (AID in yellow). The acidic, C-terminal and hydrophobic substrate-binding grooves, defined for PPP phosphatases, are labeled as A, C and H, respectively. Loops 6 (light blue) and 7 (brown) are clearly visible between the acidic and C-terminal grooves. Surface representation of the catalytic domain of CNA subunit illustrating the <italic>trans</italic>- conformation (<bold>b</bold>) and the <italic>cis</italic>- conformation (<bold>c</bold>). In these views the two catalytic metal ions and a bound phosphate molecule are clearly visible. The C-terminal tail of <italic>cis</italic>-CNA, corresponding to the extended linker, has been omitted for clarity. (d) Cartoon of the <italic>cis-/trans-</italic>CNA transition with a schematic representation of the main structural differences between the <italic>trans</italic>-CNA (upper) and <italic>cis</italic>-CNA (bottom) conformations. Strands Î²13-Î²14 are colored in light blue and green for the <italic>trans</italic>- and <italic>cis-</italic>CNA conformations, respectively. Metal ions (red balls), loop6 (light blue) and loop7 (brown), with proline 309 (green pentagon), are depicted.</p>
        </caption>
        <graphic xlink:href="pone.0134569.g004"/>
      </fig>
      <fig id="pone.0134569.g005" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0134569.g005</object-id>
        <label>Fig 5</label>
        <caption>
          <title>Mutation of loop 6 residues affects NFATc activity.</title>
          <p>Luciferase reporter gene assays in HEK 293T cells transfected with 3xNFAT-luc plasmid, pBJ5-mCNB and Flag-CNA 2â389 wild type (wt) or related mutants. ÎNIR mutant lacks the CNA PXIXIT binding region VMNIR ranging from amino acids 328 to 332. All Flag-CNA constructs bear the Y341F mutation to achieve CsA resistance unless for the specified wt. Endogenous CN activity was abolished by treating the cells with 1 Î¼M CsA 30 min before stimulation. Stimulation was achieved by treating the cells with Io/PMA/Ca<sup>2+</sup> for 6 hours. FK506 was added as a control of CN inhibition of the CNA 2â389 Y341F. Absence of cell stimulation is shown with a minus symbol (-). Three experiments were performed in triplicates. CNA wt and mutants protein levels were assessed by densitometry of the electrophoretic bands detected by western blot analysis with anti-FLAG antibody. Data is given as mean percentage of NFAT activation normalized to CNA protein levels. Stimulation of the Y341F mutant was considered as 100% value.</p>
        </caption>
        <graphic xlink:href="pone.0134569.g005"/>
      </fig>
      <p>In all the reported structures of catalytic domains from PPPs the central proline in the highly conserved SAPNY sequence shows the peptidyl <italic>trans</italic> isomer found also in the <italic>trans</italic>-CNA subunit in this work [<xref rid="pone.0134569.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0134569.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0134569.ref033" ref-type="bibr">33</xref>]. Strikingly, in the only available structure of a protein unrelated to PPP phosphatases containing a SAPNY sequence (the prokaryotic enzyme family 5-xyloglucanase, PDB codes 2JEP and 2JEQ), the peptide forms a solvent exposed turn with a central <italic>cis</italic>-proline that is essentially identical to the structure found in <italic>cis</italic>-CNA (<xref rid="pone.0134569.g003" ref-type="fig">Fig 3c</xref>). The parallel pairing of Î²14 strands from neighbor CNA subunits having to deviate from a symmetric two fold interaction can explain, at least in part, the presence of the alternative conformations. This supports the feasibility of the <italic>trans-</italic> to <italic>cis</italic> transition, not yet detected directly <italic>in vivo</italic>, when the appropriated interactions with other proteins are involved. The standard PxIxIT binding site in the <italic>trans</italic>-CNA subunit (sequence VMNIRQF starting with Val328), is occupied by the shifted sequence AAVLKYE (starting with Ala319) from the Î²14 strand of the neighbor <italic>cis</italic>-CNA (Figs <xref rid="pone.0134569.g001" ref-type="fig">1b</xref> and <xref rid="pone.0134569.g002" ref-type="fig">2b</xref>). However, the peptide <monospace>NNKAAVLKYE</monospace>, containing the sequence of Î²-14 strand of cis-CNA, does not interfere with high affinity interactions between CN and peptides or proteins containing a PxIxIT motif such a the NFATc2-derived <monospace>SPRIEIT</monospace> peptide in fluorescence polarization assays (<xref rid="pone.0134569.g006" ref-type="fig">Fig 6a</xref>) and the GSTRCAN3 (<xref rid="pone.0134569.g006" ref-type="fig">Fig 6b</xref>) or the GSTNFATc2 (<xref rid="pone.0134569.g006" ref-type="fig">Fig 6c</xref>) proteins in pull down assays. In contrast, the RCAN3-derived R3<sup>183-203</sup> peptide, which includes a PxIxIT motif, is able to disrupt CN interaction with proteins containing a PxIxIT motif. The corresponding site in the Î²14 strand of the <italic>cis</italic>-CNA subunit (AAVLKY) interacts with the NVMNIR sequence (starting with Asn327 from the Î²14 strand of the neighbor <italic>trans</italic>-CNA subunit). The reverse c<italic>is</italic>- to <italic>trans</italic>-CNA transition might be enhanced by peptidyl-prolyl isomerase enzymes (PPIs), given the accessibility of Pro309 exposed at the molecular surface (<xref rid="pone.0134569.g004" ref-type="fig">Fig 4d</xref>). In fact, a wealth of data exists that defines CN as one of the <italic>in vivo</italic> targets of FKBP12 and CypA, two ubiquitous PPIs that are known to physically interact with and modulate CN even in the absence of the FK506 and CsA immunosuppressant drugs[<xref rid="pone.0134569.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0134569.ref035" ref-type="bibr">35</xref>]. Furthermore, structures of CN in complex with either FKBP12-FK506 [<xref rid="pone.0134569.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0134569.ref012" ref-type="bibr">12</xref>] or with CypA-CsA [<xref rid="pone.0134569.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0134569.ref020" ref-type="bibr">20</xref>] place both PPIs in similar locations (<xref rid="pone.0134569.g007" ref-type="fig">Fig 7a and 7b</xref>) having access to Pro309 if the <italic>cis</italic>-CNA conformation is adopted. Docking of the structure of the complex of CypA with the Ala-<italic>cis</italic>Pro dipeptide (PDB code 2CYH) onto <italic>cis</italic>-CNA by superimposition of the Ala-<italic>cis</italic>Pro fragments of both structures indicates a close interaction between CypA and the catalytic domain of CNA (<xref rid="pone.0134569.g007" ref-type="fig">Fig 7c and 7d</xref>), which can explain why CNB is dispensable for the FKBP12-CN binary complex but required for the ternary complex with FK506[<xref rid="pone.0134569.ref034" ref-type="bibr">34</xref>]. A prolyl isomerization process provides a rationale for the intriguing interactions of CN and PPIs, with natural products CsA and FK506 capitalizing upon these inherent interactions[<xref rid="pone.0134569.ref034" ref-type="bibr">34</xref>]. A similar isomerization mechanism could also operate for the mammalian target of rapamycin kinase (mTOR), which forms a ternary complex with FKBP12 and the natural product rapamycin[<xref rid="pone.0134569.ref036" ref-type="bibr">36</xref>]. Phosphorylation-dependent prolyl isomerization has been proposed as a molecular timer to modulate the amplitude and duration of cellular processes[<xref rid="pone.0134569.ref037" ref-type="bibr">37</xref>]. Complex patterns of regulation could also result from prolyl isomerization and PPIs modulating Cn.</p>
      <fig id="pone.0134569.g006" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0134569.g006</object-id>
        <label>Fig 6</label>
        <caption>
          <title>The conserved <italic>cis</italic>-CNA Î²14 strand structure does not seem to include a functional PxIxIT binding site.</title>
          <p>(<bold>a</bold>) CF-SPRIEIT-CNA interaction was competed with increasing amounts of the unlabeled CNA-derived peptide <monospace>NNKAAVLKYE</monospace> from <italic>cis</italic>-CNA Î²14 strand or an RCAN3-derived PxIxIT-containing peptide (amino acids 183â203, R3<sup>183-203</sup>) and assessed by fluorescence anisotropy. Anisotropic fluorescence emission values (mP) are represented as mean Â±SEM of two independent experiments performed in triplicates. An unrelated peptide was included as negative control. Endogenous CNA (<bold>b</bold>) or Flag-CNA 2â389 (<bold>c</bold>) pull down assays using GST-RCAN3 (GSTR3) (<bold>b</bold>) or GST-NFATc2 (GSTNFATc2) (<bold>c</bold>) as bait and competed with increasing concentrations of <italic>cis-</italic>CNA-derived peptide <monospace>NNKAAVLKYE</monospace> or RCAN3-derived peptide (R3<sup>183-203</sup>). GST alone was used as negative control. Ponceau staining of the membrane shows equal GST fusion protein loading of each lane.</p>
        </caption>
        <graphic xlink:href="pone.0134569.g006"/>
      </fig>
      <fig id="pone.0134569.g007" orientation="portrait" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0134569.g007</object-id>
        <label>Fig 7</label>
        <caption>
          <title>Complexes of CN with peptidyl-prolyl isomerases (PPIs) Cyclophilin A (CypA) and FKBP12.</title>
          <p>The crystal structures of CN (surface representation) in complex with (<bold>a</bold>) CypA and the immunosuppressant drug cyclosporine A (CsA) (PDB code 1M63) and (<bold>b</bold>) FKBP12 and the immunosuppressant drug FK506 (PDB code 1TCO) place both PPIs in similar locations with direct access to Pro309 if CNA adopts the <italic>cis</italic> conformation. The solvent accessible loop 7 in <italic>trans-</italic>CNA (blue) is absent in <italic>cis</italic>-CNA (brown), where Pro309 is placed at the tip of the Î²13-Î²14 turn. (<bold>c</bold>) Docking of the structure of the complex of CypA with the Ala-<italic>cis</italic>Pro dipeptide (PDB code 2CYH) onto <italic>cis</italic>-CNA by superimposition of the Ala-<italic>cis</italic>Pro fragments of both structures (shown in detail in the inset). (<bold>d</bold>) The interaction between PPIs and the catalytic domain of <italic>cis</italic>-CNA requires binding at sites that are close but not identical to the ones observed in the CN-Immunosuppressant-PPI ternary complexes, which can explain why CNB is dispensable for the FKBP12-CN binary complex but required for the ternary complex with FK506 [<xref rid="pone.0134569.ref034" ref-type="bibr">34</xref>].</p>
        </caption>
        <graphic xlink:href="pone.0134569.g007"/>
      </fig>
      <p>The high sequence and structural similarities between the catalytic domains of PPPs suggests that the alternative <italic>trans</italic>- <italic>cis-</italic> conformations associated with peptidyl isomerization of the proline from the conserved SAPNY sequence observed for CNA can be common to most PPPs. In particular, interactions at the RVxF binding site of PP1 could present a similar feature to the one proposed here for the PxIxIT binding site of CN. For PPPs an increased structural versatility can help to explain how they can achieve specificity towards a large number of substrates, besides other established mechanisms [<xref rid="pone.0134569.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0134569.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0134569.ref024" ref-type="bibr">24</xref>]. It also provides a new vista for the development of therapeutic drugs with specificity directed towards one or the other of the two alternative conformers.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>pBJ5-CNB plasmid was a kind gift from Dr. J. Heitman. X-ray data collection was performed with the support of beam line PROXIMA-1 (SOLEY synchrotron). Structural data reported in this article is archived at the PDB database with reference 5C1V.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0134569.ref001">
        <label>1</label>
        <mixed-citation publication-type="journal">
<name><surname>Roy</surname><given-names>J</given-names></name>, <name><surname>Cyert</surname><given-names>MS</given-names></name>. <article-title>Cracking the phosphatase code: docking interactions determine substrate specificity</article-title>. <source>Sci Signal</source>. <year>2009</year>;<volume>2</volume>(<issue>100</issue>):<fpage>re9</fpage> Epub 2009/12/10. <pub-id pub-id-type="doi">10.1126/scisignal.2100re9</pub-id>
.<?supplied-pmid 19996458?><pub-id pub-id-type="pmid">19996458</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref002">
        <label>2</label>
        <mixed-citation publication-type="journal">
<name><surname>Shi</surname><given-names>Y</given-names></name>. <article-title>Serine/threonine phosphatases: mechanism through structure</article-title>. <source>Cell</source>. <year>2009</year>;<volume>139</volume>(<issue>3</issue>):<fpage>468</fpage>â<lpage>84</lpage>. Epub 2009/11/03. <pub-id pub-id-type="doi">10.1016/j.cell.2009.10.006</pub-id>
.<?supplied-pmid 19879837?><pub-id pub-id-type="pmid">19879837</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref003">
        <label>3</label>
        <mixed-citation publication-type="book">
<name><surname>Cohen</surname><given-names>PTW</given-names></name>. <chapter-title>Overview of protein serine/threonine phosphatases</chapter-title>
<source>Topics in Current Genetics: protein phosphatases</source>. <year>2004</year>;<volume>5</volume>(<name><surname>Arino</surname><given-names>J.</given-names></name>, <name><surname>Alexander</surname><given-names>D.R.</given-names></name>, editors. <publisher-name>Springer-Verlag</publisher-name>; <publisher-loc>BerlinâHeidelberg</publisher-loc>):<fpage>10</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0134569.ref004">
        <label>4</label>
        <mixed-citation publication-type="journal">
<name><surname>Virshup</surname><given-names>DM</given-names></name>, <name><surname>Shenolikar</surname><given-names>S</given-names></name>. <article-title>From promiscuity to precision: protein phosphatases get a makeover</article-title>. <source>Mol Cell</source>. <year>2009</year>;<volume>33</volume>(<issue>5</issue>):<fpage>537</fpage>â<lpage>45</lpage>. Epub 2009/03/17. <pub-id pub-id-type="doi">10.1016/j.molcel.2009.02.015</pub-id>
.<?supplied-pmid 19285938?><pub-id pub-id-type="pmid">19285938</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref005">
        <label>5</label>
        <mixed-citation publication-type="journal">
<name><surname>Aramburu</surname><given-names>J</given-names></name>, <name><surname>Rao</surname><given-names>A</given-names></name>, <name><surname>Klee</surname><given-names>CB</given-names></name>. <article-title>Calcineurin: from structure to function</article-title>. <source>Curr Top Cell Regul</source>. <year>2000</year>;<volume>36</volume>:<fpage>237</fpage>â<lpage>95</lpage>. Epub 2000/06/08. .<?supplied-pmid 10842755?><pub-id pub-id-type="pmid">10842755</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref006">
        <label>6</label>
        <mixed-citation publication-type="journal">
<name><surname>Borel</surname><given-names>JF</given-names></name>, <name><surname>Feurer</surname><given-names>C</given-names></name>, <name><surname>Gubler</surname><given-names>HU</given-names></name>, <name><surname>Stahelin</surname><given-names>H</given-names></name>. <article-title>Biological effects of cyclosporin A: a new antilymphocytic agent</article-title>. <source>Agents Actions</source>. <year>1976</year>;<volume>6</volume>(<issue>4</issue>):<fpage>468</fpage>â<lpage>75</lpage>. Epub 1976/07/01. .<?supplied-pmid 8969?><pub-id pub-id-type="pmid">8969</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref007">
        <label>7</label>
        <mixed-citation publication-type="journal">
<name><surname>Kino</surname><given-names>T</given-names></name>, <name><surname>Hatanaka</surname><given-names>H</given-names></name>, <name><surname>Hashimoto</surname><given-names>M</given-names></name>, <name><surname>Nishiyama</surname><given-names>M</given-names></name>, <name><surname>Goto</surname><given-names>T</given-names></name>, <name><surname>Okuhara</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>FK-506, a novel immunosuppressant isolated from a <italic>Streptomyces</italic>. I. Fermentation, isolation, and physico-chemical and biological characteristics</article-title>. <source>J Antibiot (Tokyo)</source>. <year>1987</year>;<volume>40</volume>(<issue>9</issue>):<fpage>1249</fpage>â<lpage>55</lpage>. Epub 1987/09/01. .<?supplied-pmid 2445721?><pub-id pub-id-type="pmid">2445721</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref008">
        <label>8</label>
        <mixed-citation publication-type="journal">
<name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Farmer</surname><given-names>JD</given-names></name>, <name><surname>Lane</surname><given-names>WS</given-names></name>, <name><surname>Friedman</surname><given-names>J</given-names></name>, <name><surname>Weissman</surname><given-names>I</given-names></name>, <name><surname>Schreiber</surname><given-names>SL</given-names></name>. <article-title>Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes</article-title>. <source>Cell</source>. <year>1991</year>;<volume>66</volume>:<fpage>807</fpage>â<lpage>15</lpage>.
<?supplied-pmid 1715244?><pub-id pub-id-type="pmid">1715244</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref009">
        <label>9</label>
        <mixed-citation publication-type="journal">
<name><surname>Gaston</surname><given-names>RS</given-names></name>. <article-title>Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2009</year>;<volume>4</volume>(<issue>12</issue>):<fpage>2029</fpage>â<lpage>34</lpage>. Epub 2009/10/24. <pub-id pub-id-type="doi">10.2215/CJN.03820609</pub-id>
.<?supplied-pmid 19850771?><pub-id pub-id-type="pmid">19850771</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref010">
        <label>10</label>
        <mixed-citation publication-type="journal">
<name><surname>Perrino</surname><given-names>BA</given-names></name>. <article-title>Regulation of calcineurin phosphatase activity by its autoinhibitory domain</article-title>. <source>Arch Biochem Biophys</source>. <year>1999</year>;<volume>372</volume>(<issue>1</issue>):<fpage>159</fpage>â<lpage>65</lpage>. Epub 1999/11/24. <pub-id pub-id-type="doi">10.1006/abbi.1999.1485</pub-id>
.<?supplied-pmid 10562429?><pub-id pub-id-type="pmid">10562429</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref011">
        <label>11</label>
        <mixed-citation publication-type="journal">
<name><surname>Kissinger</surname><given-names>CR</given-names></name>, <name><surname>Parge</surname><given-names>HE</given-names></name>, <name><surname>Knighton</surname><given-names>DR</given-names></name>, <name><surname>Lewis</surname><given-names>CT</given-names></name>, <name><surname>Pelletier</surname><given-names>LA</given-names></name>, <name><surname>Tempczyk</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex</article-title>. <source>Nature</source>. <year>1995</year>;<volume>378</volume>(<issue>6557</issue>):<fpage>641</fpage>â<lpage>4</lpage>. Epub 1995/12/07. <pub-id pub-id-type="doi">10.1038/378641a0</pub-id>
.<?supplied-pmid 8524402?><pub-id pub-id-type="pmid">8524402</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref012">
        <label>12</label>
        <mixed-citation publication-type="journal">
<name><surname>Griffith</surname><given-names>JP</given-names></name>, <name><surname>Kim</surname><given-names>JL</given-names></name>, <name><surname>Kim</surname><given-names>EE</given-names></name>, <name><surname>Sintchak</surname><given-names>MD</given-names></name>, <name><surname>Thomson</surname><given-names>JA</given-names></name>, <name><surname>Fitzgibbon</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex</article-title>. <source>Cell</source>. <year>1995</year>;<volume>82</volume>(<issue>3</issue>):<fpage>507</fpage>â<lpage>22</lpage>. Epub 1995/08/11. .<?supplied-pmid 7543369?><pub-id pub-id-type="pmid">7543369</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref013">
        <label>13</label>
        <mixed-citation publication-type="journal">
<name><surname>Wei</surname><given-names>Q</given-names></name>, <name><surname>Lee</surname><given-names>EY</given-names></name>. <article-title>Mutagenesis of the L7 loop connecting beta strands 12 and 13 of calcineurin: evidence for a structural role in activity changes</article-title>. <source>Biochemistry</source>. <year>1997</year>;<volume>36</volume>(<issue>24</issue>):<fpage>7418</fpage>â<lpage>24</lpage>. Epub 1997/06/17. <pub-id pub-id-type="doi">10.1021/bi962703s</pub-id>
.<?supplied-pmid 9200689?><pub-id pub-id-type="pmid">9200689</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref014">
        <label>14</label>
        <mixed-citation publication-type="journal">
<name><surname>Xie</surname><given-names>X</given-names></name>, <name><surname>Xue</surname><given-names>C</given-names></name>, <name><surname>Huang</surname><given-names>W</given-names></name>, <name><surname>Yu</surname><given-names>D</given-names></name>, <name><surname>Wei</surname><given-names>Q</given-names></name>. <article-title>The b12-b13 loop is a key regulatory element fot the activity and properties of the catalytic domain of protein phosphatase 1 and 2B</article-title>. <source>Biol Chem</source>. <year>2006</year>;<volume>387</volume>:<fpage>1461</fpage>â<lpage>7</lpage>.
<?supplied-pmid 17081120?><pub-id pub-id-type="pmid">17081120</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref015">
        <label>15</label>
        <mixed-citation publication-type="journal">
<name><surname>Maynes</surname><given-names>JT</given-names></name>, <name><surname>Perreault</surname><given-names>KR</given-names></name>, <name><surname>Cherney</surname><given-names>MM</given-names></name>, <name><surname>Luu</surname><given-names>HA</given-names></name>, <name><surname>James</surname><given-names>MN</given-names></name>, <name><surname>Holmes</surname><given-names>CF</given-names></name>. <article-title>Crystal structure and mutagenesis of a protein phosphatase-1:calcineurin hybrid elucidate the role of the beta12-beta13 loop in inhibitor binding</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>(<issue>41</issue>):<fpage>43198</fpage>â<lpage>206</lpage>. Epub 2004/07/29. <pub-id pub-id-type="doi">10.1074/jbc.M407184200</pub-id>
.<?supplied-pmid 15280359?><pub-id pub-id-type="pmid">15280359</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref016">
        <label>16</label>
        <mixed-citation publication-type="journal">
<name><surname>Aramburu</surname><given-names>J</given-names></name>, <name><surname>Yaffe</surname><given-names>MB</given-names></name>, <name><surname>Lopez-Rodriguez</surname><given-names>C</given-names></name>, <name><surname>Cantley</surname><given-names>LC</given-names></name>, <name><surname>Hogan</surname><given-names>PG</given-names></name>, <name><surname>Rao</surname><given-names>A</given-names></name>. <article-title>Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A</article-title>. <source>Science</source>. <year>1999</year>;<volume>285</volume>(<issue>5436</issue>):<fpage>2129</fpage>â<lpage>33</lpage>. Epub 1999/09/25. .<?supplied-pmid 10497131?><pub-id pub-id-type="pmid">10497131</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref017">
        <label>17</label>
        <mixed-citation publication-type="journal">
<name><surname>Martinez-Martinez</surname><given-names>S</given-names></name>, <name><surname>Rodriguez</surname><given-names>A</given-names></name>, <name><surname>Lopez-Maderuelo</surname><given-names>MD</given-names></name>, <name><surname>Ortega-Perez</surname><given-names>I</given-names></name>, <name><surname>Vazquez</surname><given-names>J</given-names></name>, <name><surname>Redondo</surname><given-names>JM</given-names></name>. <article-title>Blockade of NFAT activation by the second calcineurin binding site</article-title>. <source>J Biol Chem</source>. <year>2006</year>;<volume>281</volume>(<issue>10</issue>):<fpage>6227</fpage>â<lpage>35</lpage>. Epub 2006/01/13. <pub-id pub-id-type="doi">10.1074/jbc.M513885200</pub-id>
.<?supplied-pmid 16407284?><pub-id pub-id-type="pmid">16407284</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref018">
        <label>18</label>
        <mixed-citation publication-type="journal">
<name><surname>Grigoriu</surname><given-names>S</given-names></name>, <name><surname>Bond</surname><given-names>R</given-names></name>, <name><surname>Cossio</surname><given-names>P</given-names></name>, <name><surname>Chen</surname><given-names>JA</given-names></name>, <name><surname>Ly</surname><given-names>N</given-names></name>, <name><surname>Hummer</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin</article-title>. <source>PLoS Biol</source>. <year>2013</year>;<volume>11</volume>(<issue>2</issue>):<fpage>e1001492</fpage> Epub 2013/03/08. <pub-id pub-id-type="doi">10.1371/journal.pbio.1001492</pub-id>
<?supplied-pmid 23468591?><pub-id pub-id-type="pmid">23468591</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref019">
        <label>19</label>
        <mixed-citation publication-type="journal">
<name><surname>Jin</surname><given-names>L</given-names></name>, <name><surname>Harrison</surname><given-names>SC</given-names></name>. <article-title>Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2002</year>;<volume>99</volume>(<issue>21</issue>):<fpage>13522</fpage>â<lpage>6</lpage>. Epub 2002/10/03. <pub-id pub-id-type="doi">10.1073/pnas.212504399</pub-id>
<?supplied-pmid 12357034?><pub-id pub-id-type="pmid">12357034</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref020">
        <label>20</label>
        <mixed-citation publication-type="journal">
<name><surname>Huai</surname><given-names>Q</given-names></name>, <name><surname>Kim</surname><given-names>HY</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Mondragon</surname><given-names>A</given-names></name>, <name><surname>Liu</surname><given-names>JO</given-names></name>, <etal>et al</etal>
<article-title>Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2002</year>;<volume>99</volume>(<issue>19</issue>):<fpage>12037</fpage>â<lpage>42</lpage>. Epub 2002/09/10. <pub-id pub-id-type="doi">10.1073/pnas.192206699</pub-id>
<?supplied-pmid 12218175?><pub-id pub-id-type="pmid">12218175</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref021">
        <label>21</label>
        <mixed-citation publication-type="journal">
<name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Rao</surname><given-names>A</given-names></name>, <name><surname>Harrison</surname><given-names>SC</given-names></name>, <name><surname>Hogan</surname><given-names>PG</given-names></name>. <article-title>Structure of calcineurin in complex with PVIVIT peptide: portrait of a low-affinity signalling interaction</article-title>. <source>J Mol Biol</source>. <year>2007</year>;<volume>369</volume>(<issue>5</issue>):<fpage>1296</fpage>â<lpage>306</lpage>. Epub 2007/05/15. <pub-id pub-id-type="doi">10.1016/j.jmb.2007.04.032</pub-id>
.<?supplied-pmid 17498738?><pub-id pub-id-type="pmid">17498738</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref022">
        <label>22</label>
        <mixed-citation publication-type="journal">
<name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Pink</surname><given-names>MD</given-names></name>, <name><surname>Murphy</surname><given-names>JG</given-names></name>, <name><surname>Stein</surname><given-names>A</given-names></name>, <name><surname>Dell'Acqua</surname><given-names>ML</given-names></name>, <name><surname>Hogan</surname><given-names>PG</given-names></name>. <article-title>Balanced interactions of calcineurin with AKAP79 regulate Ca2+-calcineurin-NFAT signaling</article-title>. <source>Nat Struct Mol Biol</source>. <year>2012</year>;<volume>19</volume>(<issue>3</issue>):<fpage>337</fpage>â<lpage>45</lpage>. Epub 2012/02/22. <pub-id pub-id-type="doi">10.1038/nsmb.2238</pub-id>
<?supplied-pmid 22343722?><pub-id pub-id-type="pmid">22343722</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref023">
        <label>23</label>
        <mixed-citation publication-type="journal">
<name><surname>Takeuchi</surname><given-names>K</given-names></name>, <name><surname>Roehrl</surname><given-names>MH</given-names></name>, <name><surname>Sun</surname><given-names>ZY</given-names></name>, <name><surname>Wagner</surname><given-names>G</given-names></name>. <article-title>Structure of the calcineurin-NFAT complex: defining a T cell activation switch using solution NMR and crystal coordinates</article-title>. <source>Structure</source>. <year>2007</year>;<volume>15</volume>(<issue>5</issue>):<fpage>587</fpage>â<lpage>97</lpage>. Epub 2007/05/16. <pub-id pub-id-type="doi">10.1016/j.str.2007.03.015</pub-id>
<?supplied-pmid 17502104?><pub-id pub-id-type="pmid">17502104</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref024">
        <label>24</label>
        <mixed-citation publication-type="journal">
<name><surname>Peti</surname><given-names>W</given-names></name>, <name><surname>Nairn</surname><given-names>AC</given-names></name>, <name><surname>Page</surname><given-names>R</given-names></name>. <article-title>Structural basis for protein phosphatase 1 regulation and specificity</article-title>. <source>Febs J</source>. <year>2013</year>;<volume>280</volume>(<issue>2</issue>):<fpage>596</fpage>â<lpage>611</lpage>. Epub 2012/01/31. <pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08509.x</pub-id>
<?supplied-pmid 22284538?><pub-id pub-id-type="pmid">22284538</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref025">
        <label>25</label>
        <mixed-citation publication-type="journal">
<name><surname>Mulero</surname><given-names>MC</given-names></name>, <name><surname>Aubareda</surname><given-names>A</given-names></name>, <name><surname>Orzaez</surname><given-names>M</given-names></name>, <name><surname>Messeguer</surname><given-names>J</given-names></name>, <name><surname>Serrano-Candelas</surname><given-names>E</given-names></name>, <name><surname>Martinez-Hoyer</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity</article-title>. <source>J Biol Chem</source>. <year>2009</year>;<volume>284</volume>(<issue>14</issue>):<fpage>9394</fpage>â<lpage>401</lpage>. Epub 2009/02/05. <pub-id pub-id-type="doi">10.1074/jbc.M805889200</pub-id>
<?supplied-pmid 19189965?><pub-id pub-id-type="pmid">19189965</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref026">
        <label>26</label>
        <mixed-citation publication-type="journal">
<name><surname>Battye</surname><given-names>TG</given-names></name>, <name><surname>Kontogiannis</surname><given-names>L</given-names></name>, <name><surname>Johnson</surname><given-names>O</given-names></name>, <name><surname>Powell</surname><given-names>HR</given-names></name>, <name><surname>Leslie</surname><given-names>AG</given-names></name>. <article-title>iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2011</year>;<volume>67</volume>(<issue>Pt 4</issue>):<fpage>271</fpage>â<lpage>81</lpage>. Epub 2011/04/05. <pub-id pub-id-type="doi">10.1107/S0907444910048675</pub-id>
<?supplied-pmid 21460445?><pub-id pub-id-type="pmid">21460445</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref027">
        <label>27</label>
        <mixed-citation publication-type="journal">
<name><surname>Lebedev</surname><given-names>AA</given-names></name>, <name><surname>Vagin</surname><given-names>AA</given-names></name>, <name><surname>Murshudov</surname><given-names>GN</given-names></name>. <article-title>Model preparation in MOLREP and examples of model improvement using X-ray data</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2008</year>;<volume>64</volume>(<issue>Pt 1</issue>):<fpage>33</fpage>â<lpage>9</lpage>. Epub 2007/12/21. <pub-id pub-id-type="doi">10.1107/S0907444907049839</pub-id>
<?supplied-pmid 18094465?><pub-id pub-id-type="pmid">18094465</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref028">
        <label>28</label>
        <mixed-citation publication-type="journal">
<name><surname>Murshudov</surname><given-names>GN</given-names></name>, <name><surname>Skubak</surname><given-names>P</given-names></name>, <name><surname>Lebedev</surname><given-names>AA</given-names></name>, <name><surname>Pannu</surname><given-names>NS</given-names></name>, <name><surname>Steiner</surname><given-names>RA</given-names></name>, <name><surname>Nicholls</surname><given-names>RA</given-names></name>, <etal>et al</etal>
<article-title>REFMAC5 for the refinement of macromolecular crystal structures</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2011</year>;<volume>67</volume>(<issue>Pt 4</issue>):<fpage>355</fpage>â<lpage>67</lpage>. Epub 2011/04/05. <pub-id pub-id-type="doi">10.1107/S0907444911001314</pub-id>
<?supplied-pmid 21460454?><pub-id pub-id-type="pmid">21460454</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref029">
        <label>29</label>
        <mixed-citation publication-type="journal">
<name><surname>Emsley</surname><given-names>P</given-names></name>, <name><surname>Cowtan</surname><given-names>K</given-names></name>. <article-title>Coot: model-building tools for molecular graphics</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>. <year>2004</year>;<volume>60</volume>(<issue>Pt 12 Pt 1</issue>):<fpage>2126</fpage>â<lpage>32</lpage>. Epub 2004/12/02. <pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id>
.<?supplied-pmid 15572765?><pub-id pub-id-type="pmid">15572765</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref030">
        <label>30</label>
        <mixed-citation publication-type="journal">
<name><surname>Martinez-Hoyer</surname><given-names>S</given-names></name>, <name><surname>Aranguren-Ibanez</surname><given-names>A</given-names></name>, <name><surname>Garcia-Garcia</surname><given-names>J</given-names></name>, <name><surname>Serrano-Candelas</surname><given-names>E</given-names></name>, <name><surname>Vilardell</surname><given-names>J</given-names></name>, <name><surname>Nunes</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Protein kinase CK2-dependent phosphorylation of the human Regulators of Calcineurin reveals a novel mechanism regulating the calcineurin-NFATc signaling pathway</article-title>. <source>Biochim Biophys Acta</source>. <year>2013</year>;<volume>1833</volume>(<issue>10</issue>):<fpage>2311</fpage>â<lpage>21</lpage>. Epub 2013/06/05. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2013.05.021</pub-id>
.<?supplied-pmid 23732701?><pub-id pub-id-type="pmid">23732701</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref031">
        <label>31</label>
        <mixed-citation publication-type="journal">
<name><surname>Pal</surname><given-names>D</given-names></name>, <name><surname>Chakrabarti</surname><given-names>P</given-names></name>. <article-title>Cis peptide bonds in proteins: residues involved, their conformations, interactions and locations</article-title>. <source>J Mol Biol</source>. <year>1999</year>;<volume>294</volume>(<issue>1</issue>):<fpage>271</fpage>â<lpage>88</lpage>. Epub 1999/11/11. <pub-id pub-id-type="doi">10.1006/jmbi.1999.3217</pub-id>
.<?supplied-pmid 10556045?><pub-id pub-id-type="pmid">10556045</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref032">
        <label>32</label>
        <mixed-citation publication-type="journal">
<name><surname>Chan</surname><given-names>CP</given-names></name>, <name><surname>Gallis</surname><given-names>B</given-names></name>, <name><surname>Blumenthal</surname><given-names>DK</given-names></name>, <name><surname>Pallen</surname><given-names>CJ</given-names></name>, <name><surname>Wang</surname><given-names>JH</given-names></name>, <name><surname>Krebs</surname><given-names>EG</given-names></name>. <article-title>Characterization of the phosphotyrosyl protein phosphatase activity of calmodulin-dependent protein phosphatase</article-title>. <source>J Biol Chem</source>. <year>1986</year>;<volume>261</volume>(<issue>21</issue>):<fpage>9890</fpage>â<lpage>5</lpage>. .<?supplied-pmid 2426255?><pub-id pub-id-type="pmid">2426255</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref033">
        <label>33</label>
        <mixed-citation publication-type="journal">
<name><surname>Egloff</surname><given-names>MP</given-names></name>, <name><surname>Johnson</surname><given-names>DF</given-names></name>, <name><surname>Moorhead</surname><given-names>G</given-names></name>, <name><surname>Cohen</surname><given-names>PT</given-names></name>, <name><surname>Cohen</surname><given-names>P</given-names></name>, <name><surname>Barford</surname><given-names>D</given-names></name>. <article-title>Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1</article-title>. <source>Embo J</source>. <year>1997</year>;<volume>16</volume>(<issue>8</issue>):<fpage>1876</fpage>â<lpage>87</lpage>. Epub 1997/04/15. <pub-id pub-id-type="doi">10.1093/emboj/16.8.1876</pub-id>
<?supplied-pmid 9155014?><pub-id pub-id-type="pmid">9155014</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref034">
        <label>34</label>
        <mixed-citation publication-type="journal">
<name><surname>Cardenas</surname><given-names>ME</given-names></name>, <name><surname>Hemenway</surname><given-names>C</given-names></name>, <name><surname>Muir</surname><given-names>RS</given-names></name>, <name><surname>Ye</surname><given-names>R</given-names></name>, <name><surname>Fiorentino</surname><given-names>D</given-names></name>, <name><surname>Heitman</surname><given-names>J</given-names></name>. <article-title>Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands</article-title>. <source>Embo J</source>. <year>1994</year>;<volume>13</volume>(<issue>24</issue>):<fpage>5944</fpage>â<lpage>57</lpage>. Epub 1994/12/15. <?supplied-pmid 7529175?><pub-id pub-id-type="pmid">7529175</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref035">
        <label>35</label>
        <mixed-citation publication-type="journal">
<name><surname>Stie</surname><given-names>J</given-names></name>, <name><surname>Fox</surname><given-names>D</given-names></name>. <article-title>Calcineurin regulation in fungi and beyond</article-title>. <source>Eukaryot Cell</source>. <year>2008</year>;<volume>7</volume>(<issue>2</issue>):<fpage>177</fpage>â<lpage>86</lpage>. Epub 2007/12/11. <pub-id pub-id-type="doi">10.1128/EC.00326-07</pub-id>
<?supplied-pmid 18065652?><pub-id pub-id-type="pmid">18065652</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref036">
        <label>36</label>
        <mixed-citation publication-type="journal">
<name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Rudge</surname><given-names>DG</given-names></name>, <name><surname>Koos</surname><given-names>JD</given-names></name>, <name><surname>Vaidialingam</surname><given-names>B</given-names></name>, <name><surname>Yang</surname><given-names>HJ</given-names></name>, <name><surname>Pavletich</surname><given-names>NP</given-names></name>. <article-title>mTOR kinase structure, mechanism and regulation</article-title>. <source>Nature</source>. <year>2013</year>;<volume>497</volume>(<issue>7448</issue>):<fpage>217</fpage>â<lpage>23</lpage>. Epub 2013/05/03. <pub-id pub-id-type="doi">10.1038/nature12122</pub-id>
.<?supplied-pmid 23636326?><pub-id pub-id-type="pmid">23636326</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref037">
        <label>37</label>
        <mixed-citation publication-type="journal">
<name><surname>Lu</surname><given-names>KP</given-names></name>, <name><surname>Finn</surname><given-names>G</given-names></name>, <name><surname>Lee</surname><given-names>TH</given-names></name>, <name><surname>Nicholson</surname><given-names>LK</given-names></name>. <article-title>Prolyl cis-trans isomerization as a molecular timer</article-title>. <source>Nat Chem Biol</source>. <year>2007</year>;<volume>3</volume>(<issue>10</issue>):<fpage>619</fpage>â<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2007.35</pub-id>
.<?supplied-pmid 17876319?><pub-id pub-id-type="pmid">17876319</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref038">
        <label>38</label>
        <mixed-citation publication-type="journal">
<name><surname>Katoh</surname><given-names>K</given-names></name>, <name><surname>Asimenos</surname><given-names>G</given-names></name>, <name><surname>Toh</surname><given-names>H</given-names></name>. <article-title>Multiple alignment of DNA sequences with MAFFT</article-title>. <source>Methods Mol Biol</source>. <year>2009</year>;<volume>537</volume>:<fpage>39</fpage>â<lpage>64</lpage>. Epub 2009/04/21. <pub-id pub-id-type="doi">10.1007/978-1-59745-251-9_3</pub-id>
.<?supplied-pmid 19378139?><pub-id pub-id-type="pmid">19378139</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0134569.ref039">
        <label>39</label>
        <mixed-citation publication-type="journal">
<name><surname>Waterhouse</surname><given-names>AM</given-names></name>, <name><surname>Procter</surname><given-names>JB</given-names></name>, <name><surname>Martin</surname><given-names>DM</given-names></name>, <name><surname>Clamp</surname><given-names>M</given-names></name>, <name><surname>Barton</surname><given-names>GJ</given-names></name>. <article-title>Jalview Version 2âa multiple sequence alignment editor and analysis workbench</article-title>. <source>Bioinformatics</source>. <year>2009</year>;<volume>25</volume>(<issue>9</issue>):<fpage>1189</fpage>â<lpage>91</lpage>. Epub 2009/01/20. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp033</pub-id>
<?supplied-pmid 19151095?><pub-id pub-id-type="pmid">19151095</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>